The SPIRIT II Study - A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary.
boston scientific2003_annual
boston scientific2004_annual_financial
Cobalt-Chromium Paclitaxel-eluting Stent vs. identical BMS
boston scientific07AR
EXCELLA BD Randomized Trial 12-month Results Elixir Medical Confidential Ricardo Costa, MD On behalf of the EXCELLA BD Investigators.
YUKON Choice PC ® Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer.
2 March 2009 IEOR 190G Vivian Tang. Background Boston Scientific Bruce Saffran Drug-Eluting Stent Technology Patent Case Verdict.
Contact: Ofir Paz, CEO inspire-md
Saffran vs. Boston Scientific
